## Procedural steps taken and scientific information after the authorisation

## Changes made after 01/11/2002

## MAJOR CHANGES<sup>1</sup>

		Char	nges made after 01/11/2002	
			Ultratard	riseo
MAJOR (	CHANGES <sup>1</sup>			oris
No	Scope	Opinion issued on	Commission Decision Issued/ amended on	Product Summary Information affected <sup>2</sup>
II/0002	Change(s) to container	25/09/2003	01/10/2003	AV I
II/0001	Change(s) to the manufacturing process for the active substance Change(s) to the test method(s) and/or specifications for the active substance Change(s) to shelf-life or storage conditions	25/09/2003	01/10/2003	er c.
MINOR C	CHANGES <sup>3</sup>	roduc	$0^{\prime}$	
<b>Fhere hav</b>	e been no minor changes.			
	8			
		AU-		
	、			
	N CIVI			
	Medicinal P			

## **MINOR CHANGES**<sup>3</sup>

<sup>&</sup>lt;sup>1</sup> Major changes e.g. Type II variations, Annex II applications, Renewals and Annual Reassessments <sup>2</sup> SPC (Summary of Product Characteristics), Labelling, PL (Package Leaflet)

<sup>&</sup>lt;sup>3</sup> Minor changes e.g. Type I variations and Notifications